Dendreon News

In early 2007 there was a groundbreaking cancer vaccine that created a substantial amount of buzz in the medical and investment communities.

Over the last six months I have been one of ImmunoCellular Therapeutics more public supporters.

The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com . If you are unable to listen to the live webcast, it will be archived on the site following the presentation.

VeriFone Systems, Inc : Deutsche Bank recommends selling shares of VeriFone following the company's Q1 results and reiterates a $40 price target on the stock.

Myrexis is an early-stage pharmaceutical company that focuses on the development of anti-cancer drugs whose shares are trading -41.00 % from their 52-week high .

Without a doubt, Dendreon is one of the most controversial stocks in the market today.

So far, 2012 has been the best year for the biotechnology and drugs industry. So many stocks surged in the last four months based on clinical trial results, FDA approvals, FDA advisory committee recommendations, European commission approvals, recommendations from independent committees, partnerships with big pharmaceuticals, acquisitions, and so ... (more)

Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors.

Recently considered biotech's immunotherapy darling, shares of Dendreon Corporation have been taking a beating.

Other equities research analysts have also recently issued reports about the stock.

In yesterday's article , I outlined how prostate cancer patients are treated. Urologists "own" the patient until the point they are broadly metastatic and symptomatic.

Since my last article in February about Myrexis we have seen a small pop in the share price and a subsequent drop as well.

Green MountainA feels comfortable in the North American market. The CEO of the company, Larry Blanford, says he "feels very good" about the company's position amid competition, and he states that he is "not concerned" about competitive brewers in the national market, but he constantly evaluates the competitive market.

"Sipuleucel-T in African Americans: A Subgroup Analysis of Three Phase 3 Trials of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer," abstract #953. Moderated Poster Session, Prostate Cancer: Advanced III from 10:30 a.m. to 12:30 p.m. ET on Monday, May 21, 2012.

I'm currently attending the American Urology Association annual meeting in Atlanta.

Spectra Energy LP : RBC Capital Mkts initiated coverage of this company with a rating of Sector Perform and a price target of $32. DCP Midstream : RBC Capital Mkts initiated coverage of this company with a rating of Outperform and a price target of $53. Tower Semicon : Maxim Group initiated coverage of this company with a rating of Buy and a price ... (more)

The FDA grants final approval to Perrigo's abbreviated new drug application for Lansoprazole capsules for the treatment of frequent reflux, and shipments to customers began immediately.

Autodesk, Inc. A : Although software developer Autodesk reported in-line first quarter earnings per share, it is showing weakness in some locations.

Posted in : Earnings , Long Ideas , News , Guidance , Short Ideas , FDA , Legal , IPOs , Movers , Tech , Trading Ideas , Best of Benzinga In recent years, traders and investors have increasingly turned to social media to discuss their investments.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Shares in Dendreon Corp.